Dr. Reddy’s Laboratories Ltd is a leading India-based pharmaceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars and differentiated formulations.
Financial Results:
Dr Reddys Laboratories Ltd reported Revenues for Q2FY25 of ₹8,038.00 Crores up from ₹6,903.00 Crore year on year, a rise of 16.44%.
Total Expenses for Q2FY25 of ₹6,435.00 Crores up from ₹5,305.00 Crores year on year, a rise of 21.3%.
Consolidated Net Profit of ₹1,342.00 Crores down 9.45% from ₹1,482.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹15.05, down 15.31% from ₹17.77 in the same quarter of the previous year.